Filtered By:
Source: European Heart Journal

This page shows you your search results in order of date. This is page number 18.

Order by Relevance | Date

Total 332 results found since Jan 2013.

CardioPulse Articles * New oral anticoagulants for non-valvular atrial fibrillation: harder to handle than expected * Once-daily edoxaban: a safer option than well-managed warfarin for patients with atrial fibrillation? * The Quick Test: 80 years on * Apixaban: a new direct oral anticoagulant for stroke prevention in atrial fibrillation * Novel oral anticoagulants in the emergency room
Source: European Heart Journal - July 21, 2014 Category: Cardiology Tags: CardioPulse Source Type: research

Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatment with vitamin K antagonists: results from the AVERROES trial
Conclusion The efficacy and safety of apixaban compared with aspirin is consistent in subgroups of patients who have previously attempted but failed VKA therapy, irrespective of the reason for discontinuation.
Source: European Heart Journal - July 21, 2014 Category: Cardiology Authors: Coppens, M., Synhorst, D., Eikelboom, J. W., Yusuf, S., Shestakovska, O., Connolly, S. J. Tags: Atrial fibrillation Source Type: research

Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial
Conclusion The benefits of apixaban vs. warfarin were consistent in patients with AF regardless of age. Owing to the higher risk at older age, the absolute benefits of apixaban were greater in the elderly.
Source: European Heart Journal - July 21, 2014 Category: Cardiology Authors: Halvorsen, S., Atar, D., Yang, H., De Caterina, R., Erol, C., Garcia, D., Granger, C. B., Hanna, M., Held, C., Husted, S., Hylek, E. M., Jansky, P., Lopes, R. D., Ruzyllo, W., Thomas, L., Wallentin, L. Tags: Atrial fibrillation Source Type: research

Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial
Conclusion Among high-risk patients with atrial fibrillation who experienced major bleeding in ROCKET AF, the use of FFP and PCC was less among those allocated rivaroxaban compared with warfarin. However, use of PRBCs and outcomes after bleeding were similar among patients randomized to rivaroxaban or to warfarin.
Source: European Heart Journal - July 21, 2014 Category: Cardiology Authors: Piccini, J. P., Garg, J., Patel, M. R., Lokhnygina, Y., Goodman, S. G., Becker, R. C., Berkowitz, S. D., Breithardt, G., Hacke, W., Halperin, J. L., Hankey, G. J., Nessel, C. C., Mahaffey, K. W., Singer, D. E., Califf, R. M., Fox, K. A. A., on behalf of t Tags: Atrial fibrillation Source Type: research

Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes
Conclusion Patients initiating warfarin may be at an increased risk of stroke during the first 30 days of treatment, supporting the biological plausibility of a transient hypercoagulable state at the start of the treatment, although additional studies are needed to confirm these findings.
Source: European Heart Journal - July 21, 2014 Category: Cardiology Authors: Azoulay, L., Dell'Aniello, S., Simon, T. A., Renoux, C., Suissa, S. Tags: Atrial fibrillation Source Type: research

Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation
Conclusions Based on randomized trial data, apixaban is a cost-effective alternative to warfarin and aspirin, in VKA suitable and VKA unsuitable patients with AF, respectively.
Source: European Heart Journal - July 21, 2014 Category: Cardiology Authors: Dorian, P., Kongnakorn, T., Phatak, H., Rublee, D. A., Kuznik, A., Lanitis, T., Liu, L. Z., Iloeje, U., Hernandez, L., Lip, G. Y. H. Tags: BASIC SCIENCE Source Type: research

Lipid lowering in patients with treatment-resistant hypertension: an analysis from the Treating to New Targets (TNT) trial
Conclusion In subjects with TRH, intensive lipid lowering with atorvastatin 80 mg is associated with a significant reduction in cardiovascular events.
Source: European Heart Journal - July 15, 2014 Category: Cardiology Authors: Bangalore, S., Fayyad, R., Laskey, R., DeMicco, D., Deedwania, P., Kostis, J. B., Messerli, F. H., Treating to New Targets Steering Committee and Investigators Tags: Heart failure/cardiomyopathy Source Type: research

Treating hypertension in the very elderly--benefits, risks, and future directions, a focus on the hypertension in the very elderly trial
Although the number of individuals reaching 80 who are considered to be healthy is increasing, the very elderly are likely to have long-term conditions, to report symptoms and/or be taking at least one regular medication. The impact of antihypertensive treatment has to be taken into account in this context. The treatment regimen in Hypertension in the Very Elderly Trial with a goal blood pressure of <150/80 mmHg has been shown to provide benefits in terms of a reduction in risk of total mortality, stroke, and cardiovascular events with potential benefits and no evidence of increased risk for fracture, dementia, depressi...
Source: European Heart Journal - July 7, 2014 Category: Cardiology Authors: Peters, R., Beckett, N., McCormack, T., Fagard, R., Fletcher, A., Bulpitt, C. Tags: Clinical update Source Type: research

Aliskiren alone or with other antihypertensives in the elderly with borderline and stage 1 hypertension: the APOLLO trial
Conclusions Sizeable reductions in BP, with potential for substantial CVD reduction, can be safely achieved using combinations of BP drugs in the elderly with normal high and Stage 1 hypertension. Clinical trial registration NCT01259297.
Source: European Heart Journal - July 7, 2014 Category: Cardiology Authors: Teo, K. K., Pfeffer, M., Mancia, G., O'Donnell, M., Dagenais, G., Diaz, R., Dans, A., Liu, L., Bosch, J., Joseph, P., Copland, I., Jung, H., Pogue, J., Yusuf, S., on behalf of the Aliskiren Prevention of Later Life Outcomes trial Investigators Tags: Hypertension Source Type: research

Renin-angiotensin system antagonists and clinical outcomes in stable coronary artery disease without heart failure
Conclusions Use of ACEI/ARB was not associated with better outcomes in stable CAD outpatients without HF. The benefit of ACEI/ARB seen in randomized clinical trials was not replicated in this large contemporary cohort, which questions their value in this specific subset.
Source: European Heart Journal - July 7, 2014 Category: Cardiology Authors: Sorbets, E., Labreuche, J., Simon, T., Delorme, L., Danchin, N., Amarenco, P., Goto, S., Meune, C., Eagle, K. A., Bhatt, D. L., Steg, P. G. Tags: Coronary artery disease Source Type: research

The German Aortic Valve Registry (GARY): in-hospital outcome
Conclusion The in-hospital outcome results of this registry show that conventional surgery yields excellent results in all risk groups and that catheter-based aortic valve replacements is an alternative to conventional surgery in high risk and elderly patients.
Source: European Heart Journal - June 21, 2014 Category: Cardiology Authors: Hamm, C. W., Mollmann, H., Holzhey, D., Beckmann, A., Veit, C., Figulla, H.-R., Cremer, J., Kuck, K.-H., Lange, R., Zahn, R., Sack, S., Schuler, G., Walther, T., Beyersdorf, F., Bohm, M., Heusch, G., Funkat, A.-K., Meinertz, T., Neumann, T., Papoutsis, K. Tags: FASTTRACK CLINICAL Source Type: research

Clinical implications of new-onset left bundle branch block after transcatheter aortic valve replacement: analysis of the PARTNER experience
Conclusion Persistent, new-onset LBBB occurred in 10.5% of patients without intraventricular baseline conduction who underwent TAVR in the PARTNER experience. New LBBB was not associated with death, repeat hospitalization, stroke, or myocardial infarction at 1 year, but was associated with a higher rate of PPI and failure of left ventricular ejection fraction to improve.
Source: European Heart Journal - June 21, 2014 Category: Cardiology Authors: Nazif, T. M., Williams, M. R., Hahn, R. T., Kapadia, S., Babaliaros, V., Rodes-Cabau, J., Szeto, W. Y., Jilaihawi, H., Fearon, W. F., Dvir, D., Dewey, T. M., Makkar, R. R., Xu, K., Dizon, J. M., Smith, C. R., Leon, M. B., Kodali, S. K. Tags: TAVI Source Type: research

Contrast-induced acute kidney injury after primary percutaneous coronary intervention: results from the HORIZONS-AMI substudy
Conclusion Contrast-induced acute kidney injury is associated with poor short- and long-term outcomes after primary percutaneous coronary intervention in STEMI.
Source: European Heart Journal - June 14, 2014 Category: Cardiology Authors: Narula, A., Mehran, R., Weisz, G., Dangas, G. D., Yu, J., Genereux, P., Nikolsky, E., Brener, S. J., Witzenbichler, B., Guagliumi, G., Clark, A. E., Fahy, M., Xu, K., Brodie, B. R., Stone, G. W. Tags: Interventional cardiology Source Type: research

CardioPulse Articles * Warfarin increases stroke risk in atrial fibrillation * Aspirin still overprescribed for stroke prevention in atrial fibrillation * Clinical Research in Cardiology: the official journal of the German Cardiac Society (Deutsche Gesellschaft fur Herz-/Kreislaufforschung) * Septic shock in infective endocarditis * Innovation in atrial fibrillation therapy
Source: European Heart Journal - June 7, 2014 Category: Cardiology Tags: CardioPulse Source Type: research

Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48
Conclusions In a contemporary AF population, LA structure and function were increasingly abnormal with a greater electrical burden of AF and higher stroke risk estimated by the CHADS2 score. Moreover, LA dysfunction was present despite normal LA size and sinus rhythm, suggesting that the assessment of LA function may add important incremental information in the evaluation of AF patients. Clinical Trial Registration: http://www.clinicaltrials.gov; ID = NCT00781391.
Source: European Heart Journal - June 7, 2014 Category: Cardiology Authors: Gupta, D. K., Shah, A. M., Giugliano, R. P., Ruff, C. T., Antman, E. M., Grip, L. T., Deenadayalu, N., Hoffman, E., Patel, I., Shi, M., Mercuri, M., Mitrovic, V., Braunwald, E., Solomon, S. D., for the Effective aNticoaGulation with factor xA next GEnerat Tags: Atrial fibrillation Source Type: research